-
Mashup Score: 4Molecular Classification of Cancers of Unknown Primary Expands and Refines Treatment Options - Tempus - 11 month(s) ago
Background: Patients with cancer of unknown primary (CUP) have a poor prognosis due to delays in diagnostic workup and empirically-selected platinum-based regimens that may not be the most active first line for the primary disease. The Tempus Tumor Origin (TO) test is a machine learning classifier that uses RNA-Seq data to identify the most likely … Continued
Source: TempusCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Molecular Classification of Cancers of Unknown Primary Expands and Refines Treatment Options - Tempus - 11 month(s) ago
Background: Patients with cancer of unknown primary (CUP) have a poor prognosis due to delays in diagnostic workup and empirically-selected platinum-based regimens that may not be the most active first line for the primary disease. The Tempus Tumor Origin (TO) test is a machine learning classifier that uses RNA-Seq data to identify the most likely … Continued
Source: TempusCategories: Hem/Oncs, Latest HeadlinesTweet-
Molecular classification of cancers of unknown primary expands and refines treatment options [Sep 11, 2022] George et al. #ESMO22 Poster 923P https://t.co/Ha5SUb8GOT & https://t.co/6vxGpOvDFh #PrecisionMedicine #CUPsm @TempusLabs
-
-
Mashup Score: 0PAVO - Tempus - 1 year(s) ago
PAVO is an open-label Phase II study investigating if the study drug, a PARP inhibitor called niraparib (Zejula), is safe and effective for certain people who have been diagnosed with an advanced solid tumor with either an inherited or tumor PALB2 mutation. All participants will receive the study drug, niraparib. Study participants will be dosed with niraparib orally once daily throughout each…
Source: TempusCategories: Hem/Oncs, Latest HeadlinesTweet-
PAVO: A Pan-Tumor PALB2 PARP Inhibitor Study -- A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations - @TempusLabs @GSK https://t.co/L3jMTYiy2o #NCT05169437 #PrecisionMedicine https://t.co/SlEmF3lH2N
-
-
Mashup Score: 0
Background: Recent studies suggest differences in outcomes among patients (pts) with metastatic breast cancer (MBC) treated with abemaciclib, ribociclib, or palbociclib, but whether these differences have a genomic basis is unknown. Here, we utilize a large real-world dataset to compare the mutational landscapes of HR+/HER2- MBC samples in which CDK4/6 inhibitor (CDK4/6i) treatment was initiated…
Source: TempusCategories: Hem/Oncs, Latest HeadlinesTweet-
Mutational Landscape of 1172 Pts w/ HR+, HER2- Met Breast Cancer Tx'd w/ CDK4/6 Inhibitors [Dec 2022] Shah et al. #SABCS22 https://t.co/il0kHWVY58 #bcsm #PrecisionMedicine @TempusLabs https://t.co/RBkLPjBz0Z
-
-
Mashup Score: 0Molecular Classification of Cancers of Unknown Primary Expands and Refines Treatment Options - Tempus - 1 year(s) ago
Background: Patients with cancer of unknown primary (CUP) have a poor prognosis due to delays in diagnostic workup and empirically-selected platinum-based regimens that may not be the most active first line for the primary disease. The Tempus Tumor Origin (TO) test is a machine learning classifier that uses RNA-Seq data to identify the most likely … Continued
Source: TempusCategories: Hem/Oncs, Latest HeadlinesTweet-
Molecular classification of cancers of unknown primary expands and refines treatment options [Sep 11, 2022] George et al. #ESMO22 Poster 923P https://t.co/Ha5SUb88Zl & https://t.co/6vxGpOv5PJ #PrecisionMedicine #CUPsm @TempusLabs
-
-
Mashup Score: 1Laboratory Developed Tests | HRD, TO, & DPYD Testing | Tempus - 1 year(s) ago
Our AI-driven algorithms platform leverages data to develop tests that help inform the treatment of cancer patients, including HRD, tumor origin and DPYD tests.
Source: TempusCategories: Hem/Oncs, Latest HeadlinesTweet-
@OncBrothers Here is some info -- https://t.co/WNje3dj3mL
-
-
Mashup Score: 0Molecular Classification of Cancers of Unknown Primary Expands and Refines Treatment Options - Tempus - 1 year(s) ago
Background: Patients with cancer of unknown primary (CUP) have a poor prognosis due to delays in diagnostic workup and empirically-selected platinum-based regimens that may not be the most active first line for the primary disease. The Tempus Tumor Origin (TO) test is a machine learning classifier that uses RNA-Seq data to identify the most likely … Continued
Source: TempusCategories: Hem/Oncs, Latest HeadlinesTweet-
Molecular classification of cancers of unknown primary expands and refines treatment options [Sep 11, 2022] George et al. #ESMO22 Poster 923P https://t.co/Ha5SUb88Zl & https://t.co/6vxGpOv5PJ #PrecisionMedicine #CUPsm @TempusLabs
-
-
Mashup Score: 1PAVO - Tempus - 1 year(s) ago
PAVO is an open-label Phase II study investigating if the study drug, a PARP inhibitor called niraparib (Zejula), is safe and effective for certain people who have been diagnosed with an advanced solid tumor with either an inherited or tumor PALB2 mutation. All participants will receive the study drug, niraparib. Study participants will be dosed with niraparib orally once daily throughout each…
Source: TempusCategories: Hem/Oncs, Latest HeadlinesTweet-
PAVO: A Pan-Tumor PALB2 PARP Inhibitor Study -- A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations - @TempusLabs @GSK https://t.co/L3jMTYj5RW #NCT05169437 #PrecisionMedicine https://t.co/rvCxMrCr2F https://t.co/d64pwQznDV
-
-
Mashup Score: 1Tempus Announces Collaboration with the Children’s Oncology Group to Expand Access to Genomic Testing for Pediatric Cancer Patients - Tempus - 2 year(s) ago
Tempus, a leader in artificial intelligence and precision medicine, today announced a collaboration with the Children’s Oncology Group (COG) – a clinical trials group, supported by the National Cancer Institute (NCI), devoted exclusively to childhood, adolescent and young adult cancer research – to assist with their Pediatric MATCH Screening Trial APEC1621SC (NCT03155620). The Pediatric MATCH ……
Source: TempusCategories: Hem/Oncs, Latest HeadlinesTweet-
Tempus Announces Collaboration with the Children’s Oncology Group to Expand Access to Genomic Testing for Pediatric Cancer Patients [Sep 20, 2022] @TempusLabs https://t.co/DZDzgy0oeT #NCT03155620 #PrecisionMedicine @COGorg @KanevaMD
-
-
Mashup Score: 0Molecular Classification of Cancers of Unknown Primary Expands and Refines Treatment Options - Tempus - 2 year(s) ago
Background: Patients with cancer of unknown primary (CUP) have a poor prognosis due to delays in diagnostic workup and empirically-selected platinum-based regimens that may not be the most active first line for the primary disease. The Tempus Tumor Origin (TO) test is a machine learning classifier that uses RNA-Seq data to identify the most likely … Continued
Source: TempusCategories: Hem/Oncs, Latest HeadlinesTweet-
Molecular classification of cancers of unknown primary expands and refines treatment options [Sep 11, 2022] George et al. #ESMO22 Poster 923P https://t.co/Ha5SUb8GOT & https://t.co/6vxGpOvDFh #PrecisionMedicine #CUPsm @TempusLabs
-
Molecular classification of cancers of unknown primary expands and refines treatment options [Sep 11, 2022] George et al. #ESMO22 Poster 923P https://t.co/Ha5SUb88Zl & https://t.co/6vxGpOv5PJ #PrecisionMedicine #CUPsm @TempusLabs